Long-term efficacy and safety of raltegravir combined with optimized background therapy in treatmentexperienced patients with drugresistant hiv infection: Week 96 results of the benchmrk 1 and 2 phase III trials

Roy T. Steigbigel; David A. Cooper; Hedy Teppler; Joseph J. Eron; Jose M. Gatell; Princy N. Kumar; Jurgen K. Rockstroh; Mauro Schlechter; Christine Katlama; Martin Markowitz; Patrick Yeni; Mona R. Loutfy; Adriano Lazzarin; Jeffrey L. Lennox; Bonaventura Clotet; Jing Zhao; Hong Wan; Rand R. Rhodes; Kim M. Strohmaier; Richard J. Barnard; Robin D. Isaacs; Bach Yen T. Nguyen

doi:10.1086/650002

Long-term efficacy and safety of raltegravir combined with optimized background therapy in treatmentexperienced patients with drugresistant hiv infection: Week 96 results of the benchmrk 1 and 2 phase III trials

Roy T. Steigbigel, David A. Cooper, Hedy Teppler, Joseph J. Eron, Jose M. Gatell, Princy N. Kumar, Jurgen K. Rockstroh, Mauro Schlechter, Christine Katlama, Martin Markowitz, Patrick Yeni, Mona R. Loutfy, Adriano Lazzarin, Jeffrey L. Lennox, Bonaventura Clotet, Jing Zhao, Hong Wan, Rand R. Rhodes, Kim M. Strohmaier, Richard J. BarnardRobin D. Isaacs, Bach Yen T. Nguyen

Departament de Medicina

Producció científica: Contribució a revista › Article › Recerca › Avaluat per experts

196 Cites (Scopus)

Resum

BENCHMRK-1 and -2 are ongoing double-blind phase III studies of raltegravir in patients experiencing failure of antiretroviral therapy with triple-class drug-resistant human immunodeficiency virus infection. At week 96 (combined data), raltegravir (400 mg twice daily) plus optimized background therapy was generally well tolerated, with superior and durable antiretroviral and immunological efficacy, compared with optimized background therapy alone. © 2010 by the Infectious Diseases Society of America. All rights reserved.

Idioma original	Anglès
Pàgines (de-a)	605-612
Revista	Clinical Infectious Diseases
Volum	50
Número	4
DOIs	https://doi.org/10.1086/650002
Estat de la publicació	Publicada - 15 de febr. 2010

SDG de les Nacions Unides

Aquest resultat contribueix als següents objectius de desenvolupament sostenible.

ODG 3 – Bona salut i benestar

Accés al document

10.1086/650002

Altres arxius i enllaços

https://www.scopus.com/pages/publications/75749107023

Fingerprint

Navegar pels temes de recerca de 'Long-term efficacy and safety of raltegravir combined with optimized background therapy in treatmentexperienced patients with drugresistant hiv infection: Week 96 results of the benchmrk 1 and 2 phase III trials'. Junts formen un fingerprint únic.

Com citar-ho

Steigbigel, R. T., Cooper, D. A., Teppler, H., Eron, J. J., Gatell, J. M., Kumar, P. N., Rockstroh, J. K., Schlechter, M., Katlama, C., Markowitz, M., Yeni, P., Loutfy, M. R., Lazzarin, A., Lennox, J. L., Clotet, B., Zhao, J., Wan, H., Rhodes, R. R., Strohmaier, K. M., ... Nguyen, B. Y. T. (2010). Long-term efficacy and safety of raltegravir combined with optimized background therapy in treatmentexperienced patients with drugresistant hiv infection: Week 96 results of the benchmrk 1 and 2 phase III trials. Clinical Infectious Diseases, 50(4), 605-612. https://doi.org/10.1086/650002

@article{b86ed3ca127e403da43e083cf243811b,

title = "Long-term efficacy and safety of raltegravir combined with optimized background therapy in treatmentexperienced patients with drugresistant hiv infection: Week 96 results of the benchmrk 1 and 2 phase III trials",

abstract = "BENCHMRK-1 and -2 are ongoing double-blind phase III studies of raltegravir in patients experiencing failure of antiretroviral therapy with triple-class drug-resistant human immunodeficiency virus infection. At week 96 (combined data), raltegravir (400 mg twice daily) plus optimized background therapy was generally well tolerated, with superior and durable antiretroviral and immunological efficacy, compared with optimized background therapy alone. {\textcopyright} 2010 by the Infectious Diseases Society of America. All rights reserved.",

author = "Steigbigel, \{Roy T.\} and Cooper, \{David A.\} and Hedy Teppler and Eron, \{Joseph J.\} and Gatell, \{Jose M.\} and Kumar, \{Princy N.\} and Rockstroh, \{Jurgen K.\} and Mauro Schlechter and Christine Katlama and Martin Markowitz and Patrick Yeni and Loutfy, \{Mona R.\} and Adriano Lazzarin and Lennox, \{Jeffrey L.\} and Bonaventura Clotet and Jing Zhao and Hong Wan and Rhodes, \{Rand R.\} and Strohmaier, \{Kim M.\} and Barnard, \{Richard J.\} and Isaacs, \{Robin D.\} and Nguyen, \{Bach Yen T.\}",

year = "2010",

month = feb,

day = "15",

doi = "10.1086/650002",

language = "English",

volume = "50",

pages = "605--612",

number = "4",

}

Steigbigel, RT, Cooper, DA, Teppler, H, Eron, JJ, Gatell, JM, Kumar, PN, Rockstroh, JK, Schlechter, M, Katlama, C, Markowitz, M, Yeni, P, Loutfy, MR, Lazzarin, A, Lennox, JL, Clotet, B, Zhao, J, Wan, H, Rhodes, RR, Strohmaier, KM, Barnard, RJ, Isaacs, RD & Nguyen, BYT 2010, 'Long-term efficacy and safety of raltegravir combined with optimized background therapy in treatmentexperienced patients with drugresistant hiv infection: Week 96 results of the benchmrk 1 and 2 phase III trials', Clinical Infectious Diseases, vol. 50, núm. 4, pàg. 605-612. https://doi.org/10.1086/650002

Long-term efficacy and safety of raltegravir combined with optimized background therapy in treatmentexperienced patients with drugresistant hiv infection: Week 96 results of the benchmrk 1 and 2 phase III trials. / Steigbigel, Roy T.; Cooper, David A.; Teppler, Hedy et al.
In: Clinical Infectious Diseases, Vol. 50, Núm. 4, 15.02.2010, pàg. 605-612.

Producció científica: Contribució a revista › Article › Recerca › Avaluat per experts

TY - JOUR

T1 - Long-term efficacy and safety of raltegravir combined with optimized background therapy in treatmentexperienced patients with drugresistant hiv infection: Week 96 results of the benchmrk 1 and 2 phase III trials

AU - Steigbigel, Roy T.

AU - Cooper, David A.

AU - Teppler, Hedy

AU - Eron, Joseph J.

AU - Gatell, Jose M.

AU - Kumar, Princy N.

AU - Rockstroh, Jurgen K.

AU - Schlechter, Mauro

AU - Katlama, Christine

AU - Markowitz, Martin

AU - Yeni, Patrick

AU - Loutfy, Mona R.

AU - Lazzarin, Adriano

AU - Lennox, Jeffrey L.

AU - Clotet, Bonaventura

AU - Zhao, Jing

AU - Wan, Hong

AU - Rhodes, Rand R.

AU - Strohmaier, Kim M.

AU - Barnard, Richard J.

AU - Isaacs, Robin D.

AU - Nguyen, Bach Yen T.

PY - 2010/2/15

Y1 - 2010/2/15

N2 - BENCHMRK-1 and -2 are ongoing double-blind phase III studies of raltegravir in patients experiencing failure of antiretroviral therapy with triple-class drug-resistant human immunodeficiency virus infection. At week 96 (combined data), raltegravir (400 mg twice daily) plus optimized background therapy was generally well tolerated, with superior and durable antiretroviral and immunological efficacy, compared with optimized background therapy alone. © 2010 by the Infectious Diseases Society of America. All rights reserved.

AB - BENCHMRK-1 and -2 are ongoing double-blind phase III studies of raltegravir in patients experiencing failure of antiretroviral therapy with triple-class drug-resistant human immunodeficiency virus infection. At week 96 (combined data), raltegravir (400 mg twice daily) plus optimized background therapy was generally well tolerated, with superior and durable antiretroviral and immunological efficacy, compared with optimized background therapy alone. © 2010 by the Infectious Diseases Society of America. All rights reserved.

UR - https://www.scopus.com/pages/publications/75749107023

U2 - 10.1086/650002

DO - 10.1086/650002

M3 - Article

SN - 1058-4838

VL - 50

SP - 605

EP - 612

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

IS - 4

ER -